The linked FDA record for this applicant centers on one submission: K263054, received September 1, 2026 and decided September 22, 2026 as substantially equivalent under product code QOF, regulation 21 CFR 866.3981, in the microbiology advisory committee. The decision summary describes the filing as a Special 510(k) covering modifications to the submitter's own Class II device, with design control information provided under The New 510(k) Paradigm. The same panel name appears in an earlier De Novo decision summary, DEN200031, which evaluated automatic Class III designation for the BioFire Respiratory Panel 2.1. [1][5][9]
The K263054 clearance and its stated scope
FDA records the applicant as Biofire Diagnostics at 515 Colorow Dr., Salt Lake City, Utah 84108, with Daisy Ramos listed as regulatory affairs contact. The device is named BIOFIRE Respiratory Panel 2.1 (RP2.1), classified Class II under product code QOF and 21 CFR 866.3981, with a decision description of Substantially Equivalent and a summary included in the filing. The clearance type is recorded as Special, and the third-party review flag is marked N. [1][2]
The decision summary frames K263054 as a submission containing information and data on modifications made to the submitter's own Class II device requiring 510(k). It states that the unmodified devices demonstrate the fundamental scientific technology has not changed, and that design control information was provided as specified in The New 510(k) Paradigm. [5]
Instrument compatibility and test format
The 510(k) summary states that BIOFIRE RP2.1 is compatible with BioFire's PCR-based in vitro diagnostic BIOFIRE FILMARRAY 2.0 and BIOFIRE FILMARRAY TORCH systems for infectious disease testing, performed through a specific software module, the BIOFIRE RP2.1 pouch module. A published BioFire procedure describes the test as a PCR-based multiplexed nucleic acid test intended for use with the BioFire 2.0 or BioFire Torch Systems for simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs collected in transport media or saline, using kit 423742. [2][8]
Targets and the earlier De Novo record
The DEN200031 decision summary lists the assay's measurands as nucleic acids of SARS-CoV-2, Adenovirus, Coronavirus 229E, HKU1, NL63 and OC43, Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A including subtypes H1, H1-2009 and H3, Influenza B, and Parainfluenza Virus 1 and 2, among others in the truncated text. That document records Class II with special controls under 21 CFR 866.3981. BioFire's own product page for the RP2.1 Panel states one test, 22 targets and results in about 45 minutes, and describes it as a multiplex molecular test; these are the publisher's claims, not independently verified here. [4][9]
Collection context and a recall entry
The MedtechLedger collection links one 510(k) record, K263054, with one Substantially Equivalent decision. This count describes the linked collection and its one-record sample; it does not establish BioFire’s total portfolio or sales. A separate FDA page is titled Class 2 Device Recall BIOFIRE Respiratory Panel 2.1 (RP2.1). That record must be consulted for its specific recall scope and dates. BioFire’s panels page describes a syndromic approach across viruses, bacteria, parasites, yeast and antimicrobial resistance genes; this is the manufacturer’s product description. [1][6][7]

